RMP1-14 is specific clone name for a rat anti-mouse PD-1 antibody. The original hybridoma was generated by immunizing Sprague Dawley rats with mouse PD-1-transfected BHK cells. A P3U1 myeloma was used as the fusion partner.
Who was it created by?
It was developed by Michael Eppihimer at the Wyeth/Genetics Institute
Where was it first published?
Authors: Eppihimer et al.
Journal Title: Expression and Regulation of the PD-L1 Immunoinhibitory Molecule on Microvascular Endothelial Cells.
Additional Info: 2002 Apr;9(2):133-45. PMID:11932780. Describes the original generation of this antibody, and its use in ELISA, flow cytometry and immunohistochemistry.
The 10F.9G2 antibody has been shown to block the interaction between PD-L1 and PD-1 and between PD-L1 and B7-1 (CD80).
A total of 331 articles have been published over the last three years citing 10F.9G2, with scientists from 210 organisations in 26 countries contributing to the research. The top authors publishing articles using 10F.9G2 in the last three years are show in Table 1 below.
Table 1: The top 10 most prolific authors citing 10F.9G2 in the last 3 years
|Wen-Fang Cheng||National Taiwan University||Taiwan|
|Chien-An Chen||National Taiwan University||Taiwan|
|Kabir Khan||University of Toronto||Canada|
|Dirk Schadendorf||University of Duisburg-Essen||Germany|
|Payal Dhar||Northwestern University||United States|
|Claudia de Lorenzo||University of Naples Federico II||Italy|
|Jun Tang||Sun Yat-sen University||China|
|Xiao-Jing Wang||University of California Davis||United States|
|Jing Wang||University of Pittsburgh||United States|
|Yang-Xin Fu||Tsinghua University||China|
A breakdown of the main locations of the authors are shown in Image 1 and 2 below. In Image 3 we show the main journals that cite work using RMP1-14.
Image 1: Citations by Country
Image 2: Citations by State (USA)
Image 3: Citations by Journal
Images kindly provided by SciLeads
Latest Research Articles Using 10F.9G2
- Jae Kim, Korea University of Science and Technology. Improving anticancer effect of aPD-L1 through lowering neutrophil infiltration by PLAG in tumor implanted with MB49 mouse urothelial carcinoma.
- Atsushi Enomoto, Nagoya University. Meflin-positive cancer-associated fibroblasts enhance tumor response to immune checkpoint blockade.
- Yun Liang, Zhejiang University. Inhibition of myeloid-derived suppressive cell function with all-trans retinoic acid enhanced anti-PD-L1 efficacy in cervical cancer.